Trials / Completed
CompletedNCT02600169
Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab
Retrospective Analysis of Response Markers and Adverse Events in a Nationwide Cohort of Advanced Melanoma Patients Treated With Pembrolizumab
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (actual)
- Sponsor
- University Medical Center Groningen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a retrospective cohort study. A database will be created from the data available of all patients that have participate in the named patient program for pembrolizumab in the Netherlands. This database will be used for analysis of response markers and for an evaluation of adverse events.
Detailed description
This study is a retrospective cohort study. A database will be created from the data available of all patients that have participate in the named patient program for pembrolizumab in the Netherlands. This database will be used for analysis of response markers and for an evaluation of adverse events.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pemprolizumab | All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma. |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2019-04-01
- Completion
- 2019-04-01
- First posted
- 2015-11-09
- Last updated
- 2024-05-06
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT02600169. Inclusion in this directory is not an endorsement.